The Revelation of Continuously Organized, Co-Overexpressed Protein-Coding Genes with Roles in Cellular Communications in Breast Cancer.

breast cancer cancer progression computational biology coregulation emerging pathways polygenic nature shared mechanisms of gene expression transcriptome

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
28 Nov 2022
Historique:
received: 21 09 2022
revised: 10 11 2022
accepted: 21 11 2022
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Many human cancers, including breast cancer, are polygenic and involve the co-dysregulation of multiple regulatory molecules and pathways. Though the overexpression of genes and amplified chromosomal regions have been closely linked in breast cancer, the notion of the co-upregulation of genes at a single locus remains poorly described. Here, we describe the co-overexpression of 34 continuously organized protein-coding genes with diverse functions at 8q.24.3(143437655-144326919) in breast and other cancer types, the CanCord34 genes. In total, 10 out of 34 genes have not been reported to be overexpressed in breast cancer. Interestingly, the overexpression of CanCord34 genes is not necessarily associated with genomic amplification and is independent of hormonal or HER2 status in breast cancer. CanCord34 genes exhibit diverse known and predicted functions, including enzymatic activities, cell viability, multipotency, cancer stem cells, and secretory activities, including extracellular vesicles. The co-overexpression of 33 of the CanCord34 genes in a multivariant analysis was correlated with poor survival among patients with breast cancer. The analysis of the genome-wide RNAi functional screening, cell dependency fitness, and breast cancer stem cell databases indicated that three diverse overexpressed CanCord34 genes, including a component of spliceosome PUF60, a component of exosome complex EXOSC4, and a ribosomal biogenesis factor BOP1, shared roles in cell viability, cell fitness, and stem cell phenotypes. In addition, 17 of the CanCord34 genes were found in the microvesicles (MVs) secreted from the mesenchymal stem cells that were primed with MDA-MB-231 breast cancer cells. Since these MVs were important in the chemoresistance and dedifferentiation of breast cancer cells into cancer stem cells, these findings highlight the significance of the CanCord34 genes in cellular communications. In brief, the persistent co-overexpression of CanCord34 genes with diverse functions can lead to the dysregulation of complementary functions in breast cancer. In brief, the present study provides new insights into the polygenic nature of breast cancer and opens new research avenues for basic, preclinical, and therapeutic studies in human cancer.

Identifiants

pubmed: 36497066
pii: cells11233806
doi: 10.3390/cells11233806
pmc: PMC9741223
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Department of Science and Technology
ID : VI-D&P/535/2015-16/TDT(G

Références

Bioinformatics. 2001 Dec;17(12):1228-9
pubmed: 11751233
PLoS Genet. 2009 Aug;5(8):e1000597
pubmed: 19680443
Int J Biol Sci. 2021 Jun 22;17(10):2606-2621
pubmed: 34326697
Clin Cancer Res. 2014 Jun 15;20(12):3118-32
pubmed: 24763612
Stem Cell Reports. 2017 Oct 10;9(4):1053-1061
pubmed: 29020613
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Oncol Rep. 2010 Jul;24(1):121-8
pubmed: 20514452
Am J Pathol. 2021 Jan;191(1):168-179
pubmed: 33039351
Stem Cell Reports. 2018 May 8;10(5):1596-1609
pubmed: 29606612
Sci Rep. 2020 Oct 14;10(1):17199
pubmed: 33057153
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Sci Rep. 2015 Aug 21;5:13413
pubmed: 26292924
Oncotarget. 2017 Dec 13;9(7):7398-7410
pubmed: 29484119
Hepatology. 2011 Jul;54(1):307-18
pubmed: 21520196
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Int J Cancer. 2022 May 15;150(10):1569-1578
pubmed: 34921726
Nature. 2016 May 25;534(7605):55-62
pubmed: 27251275
Cancer Sci. 2015 Aug;106(8):959-64
pubmed: 26052865
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20
pubmed: 25514926
Mol Endocrinol. 2010 Feb;24(2):279-85
pubmed: 19846539
Mol Cancer. 2018 Feb 23;17(1):65
pubmed: 29471829
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
J Clin Lab Anal. 2020 Jul;34(7):e23283
pubmed: 32167616
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Mol Carcinog. 2018 Dec;57(12):1780-1791
pubmed: 30155936
Cancer Res. 2009 Nov 1;69(21):8217-22
pubmed: 19843848
Nat Protoc. 2013 Aug;8(8):1551-66
pubmed: 23868073
J Cell Physiol. 2018 Jan;234(1):75-88
pubmed: 30070699
PLoS One. 2012;7(6):e38575
pubmed: 22719901
Genes (Basel). 2018 Nov 23;9(12):
pubmed: 30477135
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9742-6
pubmed: 20453196
Nucleic Acids Res. 2013 Jan;41(Database issue):D1021-6
pubmed: 23193271
Hum Genomics. 2019 Nov 7;13(1):54
pubmed: 31699156
PLoS Biol. 2012;10(12):e1001450
pubmed: 23271954
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Int J Mol Sci. 2018 Oct 15;19(10):
pubmed: 30326622
Breast Cancer Res. 2019 May 17;21(1):65
pubmed: 31101122
Br J Cancer. 2004 Jan 12;90(1):8-11
pubmed: 14710198
Breast Cancer Res. 2011 Oct 06;13(5):R97
pubmed: 21978456
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
Int J Cancer. 2015 May 1;136(9):2012-21
pubmed: 24957955
Elife. 2016 Aug 20;5:
pubmed: 27543448
Curr Pharm Des. 2015;21(10):1301-10
pubmed: 25506895
Cell Stem Cell. 2012 Jul 6;11(1):127-35
pubmed: 22770246
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Oncogene. 2017 Oct 26;36(43):5917-5926
pubmed: 28650470
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Br J Cancer. 2007 Apr 23;96(8):1258-64
pubmed: 17353917
Nucleic Acids Res. 2017 Jan 4;45(D1):D43-D50
pubmed: 27924033
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Gut. 2016 Oct;65(10):1690-701
pubmed: 26156959
Cancer Res. 2021 Mar 15;81(6):1567-1582
pubmed: 33500249
RNA Biol. 2021 Jun;18(6):833-842
pubmed: 32965163
BMC Med Genet. 2011 Dec 05;12:156
pubmed: 22142333
Cancer Manag Res. 2019 Jan 17;11:821-830
pubmed: 30697074
J Biol Chem. 2001 Mar 2;276(9):6177-84
pubmed: 11110791
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
Breast Cancer Res. 2015 Mar 20;17:43
pubmed: 25887482
Hum Genomics. 2017 Dec 21;11(1):35
pubmed: 29268782
Bioinformatics. 2007 Jul 15;23(14):1846-7
pubmed: 17496320
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
J Pathol. 2021 Jul;254(3):265-278
pubmed: 33797754
Sci Rep. 2012;2:264
pubmed: 22355776
Cancer Res. 2016 Oct 1;76(19):5832-5844
pubmed: 27569215
Int J Comput Biol Drug Des. 2013;6(1-2):60-71
pubmed: 23428474
Cancer Res. 2004 Sep 15;64(18):6416-23
pubmed: 15374949
Genes Cancer. 2010 Jun;1(6):555-9
pubmed: 21779458
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Yale J Biol Med. 2016 Dec 23;89(4):591-596
pubmed: 28018147
Mol Cancer. 2018 Jul 16;17(1):97
pubmed: 30008265
BMC Cancer. 2006 Oct 13;6:245
pubmed: 17040570
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Clin Chim Acta. 2020 Nov;510:581-592
pubmed: 32791136
Front Oncol. 2020 Oct 07;10:568015
pubmed: 33117697
Eur J Pharmacol. 2021 Nov 5;910:174444
pubmed: 34453928
Int J Biol Sci. 2020 Sep 25;16(15):3002-3017
pubmed: 33061812
Nucleic Acids Res. 2021 Jan 8;49(D1):D1365-D1372
pubmed: 33068406
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15981-6
pubmed: 17043237
Cells. 2021 Feb 18;10(2):
pubmed: 33670680
Carcinogenesis. 2014 Mar;35(3):670-82
pubmed: 24148822
Genome Res. 2021 Jan;31(1):159-169
pubmed: 33239395
Mol Cell Biol. 2003 Sep;23(17):5979-88
pubmed: 12917323
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
J Natl Cancer Inst. 2008 Jul 2;100(13):962-6
pubmed: 18577746
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188591
pubmed: 34273469

Auteurs

Aswathy Mary Paul (AM)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.
PhD Program, Manipal Academy of Higher Education, Manipal 576104, India.

Revikumar Amjesh (R)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.

Bijesh George (B)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.
PhD Program, Manipal Academy of Higher Education, Manipal 576104, India.

Deivendran Sankaran (D)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.

Oleta A Sandiford (OA)

Department of Medicine-Hematology and Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.

Pranela Rameshwar (P)

Department of Medicine-Hematology and Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.

Madhavan Radhakrishna Pillai (MR)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.

Rakesh Kumar (R)

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India.
Department of Medicine-Hematology and Oncology, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun 248016, India.
Department of Human and Molecular Genetics, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH